Evoke Pharma Inc. (NASDAQ:EVOK) reached a new 52-week high during trading on Wednesday . The company traded as high as $10.80 and last traded at $10.54, with a volume of 133,156 shares changing hands. The stock had previously closed at $10.39.

A number of research firms have commented on EVOK. Rodman & Renshaw reissued a “buy” rating and issued a $27.00 target price on shares of Evoke Pharma in a report on Monday. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a report on Friday, July 8th. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a report on Friday, July 8th. Finally, Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $17.47.

The company has a 50 day moving average price of $6.31 and a 200-day moving average price of $4.67. The company’s market capitalization is $75.88 million.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.37) earnings per share for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 5,095 shares of Evoke Pharma stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total transaction of $25,831.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.